Join RegMedNet today

Access exclusive expertise - for free!

Recruiting? Interested in a new job? Take a look at jobs from RegMedNet

Spotlight on MSCs

MSCs can be harvested from several human tissues, or derived from induced pluripotent stem cells (iPSCs), and can differentiate into a range of tissue-specific cells. Various studies have also shown the MSCs, unlike iPSCs, show few oncogenic properties, potentially making them safer as therapeutic agents. Their strong capacity for differentiation also makes MSCs useful as a tool to model disease progression and assess drug efficacy. The spotlight will aim to review the current challenges in the production of MSCs with a focus on consistency, safety and efficacy. We will also look into the clinical applications of MSCs for regenerative medicine and how these therapies are going to evolve and change healthcare in the coming years.

View Channel


Getting a regenerative medicine to the clinic requires it to have a manufacturing process that can be scaled up sufficiently for large-scale production. For cell therapies, manufacturing sites need to meet strict quality and technical capabilities, and the therapies themselves need to be generated in sufficient numbers for clinical application and survive transportation. This channel will look at techniques, technologies and processes that may help support the safe, cost-effective and large-scale production of regenerative medicines

View Channel